These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
381 related articles for article (PubMed ID: 36059239)
1. T cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscape. Kazandjian D; Kowalski A; Landgren O Leuk Lymphoma; 2022 Dec; 63(13):3032-3043. PubMed ID: 36059239 [TBL] [Abstract][Full Text] [Related]
2. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy. Cho SF; Anderson KC; Tai YT Front Immunol; 2018; 9():1821. PubMed ID: 30147690 [TBL] [Abstract][Full Text] [Related]
3. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma. Davis JA; Shockley A; Hashmi H J Oncol Pharm Pract; 2022 Jun; 28(4):960-968. PubMed ID: 35006032 [TBL] [Abstract][Full Text] [Related]
4. Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast. Landgren O; Nadeem O Adv Ther; 2023 Aug; 40(8):3291-3303. PubMed ID: 37328635 [TBL] [Abstract][Full Text] [Related]
5. Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma. Mohan M; Chakraborty R; Bal S; Nellore A; Baljevic M; D'Souza A; Pappas PG; Berdeja JG; Callander N; Costa LJ Br J Haematol; 2023 Dec; 203(5):736-746. PubMed ID: 37287117 [TBL] [Abstract][Full Text] [Related]
6. Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma: Moving Into the Future. Holstein SA; Grant SJ; Wildes TM J Clin Oncol; 2023 Sep; 41(27):4416-4429. PubMed ID: 37471687 [TBL] [Abstract][Full Text] [Related]
7. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review. Rodriguez-Otero P; van de Donk NWCJ; Pillarisetti K; Cornax I; Vishwamitra D; Gray K; Hilder B; Tolbert J; Renaud T; Masterson T; Heuck C; Kane C; Verona R; Moreau P; Bahlis N; Chari A Blood Cancer J; 2024 Feb; 14(1):24. PubMed ID: 38307865 [TBL] [Abstract][Full Text] [Related]
8. Anti-BCMA CAR-T cell-based therapies and bispecific antibodies in the immunotherapy era: are we ready for this? Martino M; Gamberi B; Antonioli E; Aquino S; Della Pepa R; Malerba L; Mangiacavalli S; Pezzatti S; Bringhen S; Zamagni E Expert Rev Hematol; 2024 Jul; 17(7):375-390. PubMed ID: 38770902 [TBL] [Abstract][Full Text] [Related]
9. An update on B-cell maturation antigen-targeted therapies in Multiple Myeloma. Martino M; Paviglianiti A Expert Opin Biol Ther; 2021 Aug; 21(8):1025-1034. PubMed ID: 33412948 [No Abstract] [Full Text] [Related]
10. Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management. Markouli M; Ullah F; Unlu S; Omar N; Lopetegui-Lia N; Duco M; Anwer F; Raza S; Dima D Curr Oncol; 2023 Jul; 30(7):6330-6352. PubMed ID: 37504327 [TBL] [Abstract][Full Text] [Related]
11. Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma. Granger K; Gaffney KJ; Davis JA J Oncol Pharm Pract; 2023 Apr; 29(3):722-726. PubMed ID: 36775940 [TBL] [Abstract][Full Text] [Related]
12. BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice. Zhou X; Rasche L; Kortüm KM; Mersi J; Einsele H Haematologica; 2023 Apr; 108(4):958-968. PubMed ID: 36263838 [TBL] [Abstract][Full Text] [Related]